J Dig Cancer Res.
2020 Jun;8(1):65-70.
Current Status of Systemic Therapy in Hepatocellular Carcinoma
- Affiliations
-
- 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
Abstract
- Although being one of the major causes of malignancy related death globally, hepatocellular carcinoma (HCC) has not received much attention in respect of novel drug development. Fortunately, several new drugs were found to be effective and tolerable in patients with advanced HCC from a number of phase 3 studies during the recent several years. Novel multi‐targeted kinase inhibitors and immune checkpoint inhibitors were approved for clinical use, and combination strategies to maximize the potent of drugs demonstrated promising antitumor activity and safety with high response rate and improved safety profile. The increased number of available agents for HCC will contribute to change of treatment strategies and prognosis of patients with advanced HCC. Still, there is a many critical questions remain unanswered. Currently ongoing trials and future studies will provide better understanding of tumor biology and optimized criteria for patient selection and combination therapies.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Systemic Therapy for Advanced Hepatocellular Carcinoma: Targeted Therapy and Immunotherapy
- Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment
- Current role of systemic therapy in transarterial chemotherapyrefractory hepatocellular carcinoma patients
- Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
- Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
